Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences
Statement of the Problem: The accidental discovery of the anticancer properties of cisplatin and its clinical introduction in the 1970s paved the way for the use of platinum based metallodrugs in chemotherapy. Second-generation analogues (e.g. carboplatin) were discovered shortly after. However, the clinical introduction of new anticancer metallodrugs has slowed down dramatically, especially considering the number of new drugs synthesized each year. Probably, the most critical factor for this slow progress is the inability to elucidate in a timely manner how metallodrugs induce tumor death, precluding the rational development of new derivatives with enhanced anticancer capabilities. Most chemotherapeutic agents exert their antitumor effect by damaging DNA and its replication machinery. Therefore, the correlation between the covalent bonding to DNA and the cytotoxicity of the metal complex remains a central step in the search for new anticancer drugs. Methodology & Theoretical Orientation: Herein, we report a strategy to follow the chemical structure and coordination of platinum-based antitumor drugs by DNA under physiological conditions, namely by means of in situ resonant X-ray emission spectroscopy (RXES). RXES is an atom specific photon-in photon-out scattering technique which avoids the tedious steps of extraction and crystallization required by conventional X-ray techniques. Conclusion & Significance: The spectroscopic method proposed by us was successfully used to validate the mechanism of action of cisplatin as well as elucidate the DNA binding of Pt103 compound that exhibits cytotoxic activity. Moreover, we showed that RXES can be used to unveil the electronic structure of metallodrugs with high resolution and sensitivity and to disentangle differences in the electronic structure of the metal canter induced by a secondary ligand stereochemistry.